Related Experiment Video
Updated: May 11, 2026

Preclinical Model of Prenatal Delta-9-Tetrahydrocannabinol Exposure to Assess Its Impact on Neurodevelopmental Outcomes
Published on: February 28, 2025
Clinical Health Messaging for Perinatal Cannabis Use: Perspectives From Postpartum Individuals With Use During Early
Shannon N Ogden1, Tara R Foti2, Monique B Does1
1Division of Research, Kaiser Permanente Northern California, Pleasanton, CA, USA.
Background:
Perinatal cannabis use has become more common in the United States. However, the evidence that associates prenatal cannabis use with increased risk for adverse maternal and child health outcomes is also growing. Therefore, it is important to include perinatal cannabis risks in standard health warnings to perinatal patients. As health messaging that resonates with perinatal individuals who use cannabis regularly has not yet been identified, further testing is needed. Therefore, we sought to gain perspectives from postpartum individuals who used cannabis regularly in early pregnancy on perinatal cannabis use health messages.
Methods:
This analysis used data from a larger qualitative study that recruited participants who were 4 to 12 months postpartum and self-reported daily or weekly cannabis use during early pregnancy (at ~8 weeks gestation) at prenatal care entry. We used a semi-structured interview guide to solicit participants' thoughts on 4 different messages containing perinatal cannabis use health information and warnings. We conducted interviews in April to May 2022. We used thematic analysis to identify key aspects of acceptable perinatal cannabis health messaging.
Results:
Sixteen participants provided feedback on the health messages. Participants were 21 to 33 years old, 6 to 11 months postpartum, and self-identified as black (n = 4), Hispanic (n = 4), and white (n = 8). None of the messages were wholly accepted across participants, but we identified 3 key aspects of acceptable health messaging for perinatal cannabis use: (1) use of neutral language and images, (2) inclusion of evidence for health risks, (3) present options or alternatives for cannabis use.
Conclusion:
Findings provide evidence for perinatal cannabis use clinical health messaging that could resonate with perinatal patients who use cannabis and encourage open dialogue with their health care providers. Further research is needed to understand the actual impact of message exposure on perinatal cannabis use.
More Related Videos
Related Concept Videos
Chemotherapy-Induced Nausea and Vomiting: Cannabinoids
Two synthetic agonists of THC,...
Teratogenicity
Development of the Oral Microbiota
Upper Respiratory Drugs: Antitussives, Expectorants, and Mucolytics
Antitussives include codeine, dextromethorphan (Robitussin), and benzonatate (Tessalon). Codeine and dextromethorphan exert their effects centrally by suppressing the cough reflex center in the medulla. Benzonatate operates peripherally within the respiratory tract by anesthetizing...
Pathophysiology of Diabetes
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility, suggesting a...

